Clinical Trial Search

Primary: Number of Participants Who Are Able to Complete THL (Paclitaxel, Trastuzumab, and Lapatinib) Without a Dose Delay or Reduction, Grade 3 or Greater QTc Prolongation — 16…

Primary: Percentage of Subjects Able to Complete > 85% of the Planned Dose on Schedule — 60 percentage of participants

Primary: Number of Patients With Congestive Heart Failure (CHF) While on Active Treatment — 0 participants

Primary: Percent of Patients Who Achieve a pCR — 19; 2; 0; 0 Participants

Primary: Disease-free Survival (DFS) Rate at 2 Years in TOP2A-amplified and in TOP2A-nonamplified HER2+ ESBC Patients Treated With TC+H. — 0.978; 0.979 probability of…

Primary: 3-year Disease Free Survival (DFS) Rate — 0.987 proportion of participant

Primary: Number Participants With Neutropenia, Graded According to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version (v)4.03 — 2…

Primary: Change in Baseline of Cancer Cell Protein Levels of Human Epidermal Growth Factor Receptor (HER) Family Members (HER1-4) Following Neoadjuvant Endocrine Therapy. — 1…

Primary: Proportion of Patients Experiencing Grade 3 or 4 Diarrhea as Measured by NCI CTCAE v3.0 — 43 percentage of patients

Primary: Pathologic Complete Response (pCR) — 27 participants

Primary: Percentage of Participants With Pathologic Complete Response (pCR) — 38.9 percentage of participants

Primary: Complete Pathological Response (pCR) Rate in Breast and Axilla According to the Miller&Payne Criteria (G5-A and G5-D). — 23.5; 47.9 percentage of participants with pCR

Primary: Pathological Complete Response After Preoperative Therapy With Herceptin/Navelbine Versus Taxotere/Carboplatin/Herceptin in Patients With HER-2 Positive Early Breast…

Primary: Description of Age — 49.2 years

Primary: Progression Free Survival (PFS) at the Time of Primary Results — 8.97; 11.30; 9.13; 13.63 Months — p=0.0010

Primary: Percentage of Participants With Disease-Free Survival (DFS) Events in Herceptin 1-Year Arm Compared to Observation: 1-Year Median Follow-Up — 12.9; 7.5 percentage of…

Primary: Pathologic Complete Response in Breast and Axillary Lymph Nodes. — 16; 14; 21; 5 Participants

Primary: Percentage of Participants With Total Pathologic Complete Response (tpCR) as Assessed by the Independent Review Committee (IRC) — 39.3; 21.8 percentage of participants…

Primary: Clinical Response — 3; 30; 11; 3 participants

Primary: Pathologic Assessment After Study Treatment — 18; 16; 30 participants

Primary: Percentage of Participants Who Achieved the Target Relative Dose Intensity (RDI) of 85% — 77.6; 90.0 Percentage of participants — p=0.1080

Primary: Pathologic Complete Response — 26 percentage of participants

Primary: Number of Participants With Disease-free Survival (DFS) Event — 127; 170 Participants

Primary: The Percentage of Patients Achieving Pathological Complete Response Defined as the Absence of Invasion Tumor Cells in the Breast and in Axillary Lymph Nodes, Regardless…

Primary: Invasive Disease-free Survival (DFS) — 42; 47 Participants

Primary: Progression-free Survival (PFS) — 14.4; 19.3 Months

Primary: Combined Rate of Microscopic pCR and Macroscopic Pathologic Complete Response (mCR) — 29 Participants

Primary: Number of Patients Who Completed All Planned Therapy — 45 participants

Primary: The Residual Cancer Burden Grade III (RCB-III). — 23; 37; 14; 6 Participants

Primary: Cardiac Saftey — 68; 67; 66; 65 percentage of LVEF